Sun Hong, Zhuang Rong-Yuan, Li Tao, Zheng Yuan-Ting, Cai Wei-Min
Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, China E-mail :
Asian Pac J Cancer Prev. 2016;17(8):3917-21.
Any association between calcium channel blockers (CCBs) and survival in cancer patients remains unclear and the results of related studies are conflicting. The objective of the study was to investigate the association between calcium channel blocker (CCB) use and survival in cancer patients.
We searched PubMed, EMBASE, Web of Science and Cochrane Library for studies published before January 2016 with terms related to CCBs and survival in cancer patients. The information was reviewed and extracted by two evaluators independently. Data from publications were extracted and used to calculate hazard ratios (HRs) for overall survival (OS). Statistical analysis was performed by using Review Manager 5.3.
There were 11 studies included in our meta-analysis. Analysis of all showed that CCBs use was not associated with survival in cancer patients (HR=1.07; 95% CI: 0.91-1.25; P=0.42). No association between CCB use and overall survival in cancer patients existed, whether in Asian (HR=1.18, 95% CI: 0.72-1.93; P=0.52) or Caucasian populations (HR=1.03, 95% CI: 0.89-1.20; P=0.66).
There is no evidence that CCB use is associated with a better or worse survival in cancer patients.
钙通道阻滞剂（CCB）与癌症患者生存率之间的任何关联仍不明确，相关研究结果相互矛盾。本研究的目的是调查使用钙通道阻滞剂（CCB）与癌症患者生存率之间的关联。
我们在PubMed、EMBASE、科学网和考克兰图书馆中检索了2016年1月之前发表的与CCB和癌症患者生存率相关的研究。由两名评估人员独立审查并提取信息。提取出版物中的数据并用于计算总生存期（OS）的风险比（HR）。使用Review Manager 5.3进行统计分析。
我们的荟萃分析纳入了11项研究。对所有研究的分析表明，使用CCB与癌症患者的生存率无关（HR = 1.07；95% CI：0.91 - 1.25；P = 0.42）。无论在亚洲人群（HR = 1.18，95% CI：0.72 - 1.93；P = 0.52）还是白种人群体中（HR = 1.03，95% CI：0.89 - 1.20；P = 0.66），使用CCB与癌症患者的总生存期均无关联。
没有证据表明使用CCB与癌症患者更好或更差的生存率相关。
Zotero 插件